U.S. flag

An official website of the United States government

Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 20

1.

CD95L derived si- and shRNAs kill cancer cells through an RNAi mechanism by targeting survival genes

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing
Platform:
GPL20301
56 Samples
Download data
Series
Accession:
GSE87817
ID:
200087817

PubMed Full text in PMC Similar studies

2.

CD95L derived si- and shRNAs kill cancer cells through an RNAi mechanism by targeting survival genes [shL3.shR6.RNAseq.lg]

(Submitter supplied) The death receptor CD95/Fas can be activated by immune cells to kill cancer cells. However, most siRNAs or shRNAs targeting either CD95 or CD95L induce DICE (Death Induced by CD95/CD95L Elimination), a form of cell death in which a combination of different cell death pathways are activated, that is selective for transformed cells, and that preferentially affects cancer stem cells. We now provide evidence that both CD95 and CD95L are part of a network of genes that contain sequences that when expressed as either siRNAs or shRNAs are toxic to cancer cells. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
16 Samples
Download data: XLSX
Series
Accession:
GSE101234
ID:
200101234

PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector

3.

CD95L derived si- and shRNAs kill cancer cells through an RNAi mechanism by targeting survival genes [FasLRNAseq.lg]

(Submitter supplied) >80% of a large number of tested siRNAs and shRNAs targeting CD95 or CD95 ligand (CD95L) induce a form of cell death that is characterized by the simultaneous activation of multiple death pathways and preferentially affects transformed and cancer stem cells. We now show that these si/shRNAs kill cancer cells through canonical RNAi by targeting the 3’UTR of critical survival genes in a unique form of off-target effect. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
4 Samples
Download data: XLSX
Series
Accession:
GSE101232
ID:
200101232

PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector

4.

CD95L derived si- and shRNAs kill cancer cells through an RNAi mechanism by targeting survival genes [shL3.shR6.RNAseq.sm]

(Submitter supplied) The death receptor CD95/Fas can be activated by immune cells to kill cancer cells. However, most siRNAs or shRNAs targeting either CD95 or CD95L induce DICE (Death Induced by CD95/CD95L Elimination), a form of cell death in which a combination of different cell death pathways are activated, that is selective for transformed cells, and that preferentially affects cancer stem cells. We now provide evidence that both CD95 and CD95L are part of a network of genes that contain sequences that when expressed as either siRNAs or shRNAs are toxic to cancer cells. more...
Organism:
Homo sapiens
Type:
Non-coding RNA profiling by high throughput sequencing
Platform:
GPL20301
16 Samples
Download data: XLSX
Series
Accession:
GSE101183
ID:
200101183

PubMed Full text in PMC Similar studies SRA Run Selector

5.

CD95L derived si- and shRNAs and the CD95L mRNA kill cancer cells through an RNAi mechanism by targeting survival genes [siL3.RNAseq.lg]

(Submitter supplied) We provide evidence that shRNAs and siRNAs derived from CD95 and CD95L preferentially target the 3' UTRs of survival genes culminating in a very robust mode of cell death we call DISE (Death Induced by Survival gene Elimination)
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
8 Samples
Download data: XLSX
Series
Accession:
GSE101167
ID:
200101167

PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector

6.

CD95L derived si- and shRNAs kill cancer cells through an RNAi mechanism by targeting survival genes [AGOpulldownRNAseq.sm]

(Submitter supplied) >80% of a large number of tested siRNAs and shRNAs targeting CD95 or CD95 ligand (CD95L) induce a form of cell death that is characterized by the simultaneous activation of multiple death pathways and preferentially affects transformed and cancer stem cells. We now show that these si/shRNAs kill cancer cells through canonical RNAi by targeting the 3’UTR of critical survival genes in a unique form of off-target effect. more...
Organism:
Homo sapiens
Type:
Non-coding RNA profiling by high throughput sequencing
Platform:
GPL20301
8 Samples
Download data: XLSX
Series
Accession:
GSE101166
ID:
200101166

PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector

7.

CD95L derived si- and shRNAs kill cancer cells through an RNAi mechanism by targeting survival genes [shL1.RNAseq.lg]

(Submitter supplied) We provide evidence that shRNAs and siRNAs derived from CD95 and CD95L preferentially target the 3' UTRs of survival genes culminating in a very robust mode of cell death we call DISE (Death Induced by Survival gene Elimination)
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
4 Samples
Download data: XLSX
Series
Accession:
GSE101157
ID:
200101157

PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector

8.

CD95L mRNA is toxic to cells

(Submitter supplied) >80% of a large number of tested siRNAs and shRNAs targeting CD95 or CD95 ligand (CD95L) induce a form of cell death that is characterized by the simultaneous activation of multiple death pathways and preferentially affects transformed and cancer stem cells. We now show that these si/shRNAs kill cancer cells through canonical RNAi by targeting the 3’UTR of critical survival genes in a unique form of off-target effect. more...
Organism:
Homo sapiens
Type:
Non-coding RNA profiling by high throughput sequencing
Platform:
GPL21290
12 Samples
Download data: XLSX
Series
Accession:
GSE114425
ID:
200114425

PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector

9.

CD95/Fas ligand mRNA is toxic to cells

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing; Other
Platform:
GPL20301
12 Samples
Download data
Series
Accession:
GSE103631
ID:
200103631

PubMed Full text in PMC Similar studies

10.

CD95L mRNA is toxic to cells [SmallRNA.CD95L.50hrs.HeyA8]

(Submitter supplied) >80% of a large number of tested siRNAs and shRNAs targeting CD95 or CD95 ligand (CD95L) induce a form of cell death that is characterized by the simultaneous activation of multiple death pathways and preferentially affects transformed and cancer stem cells. We now show that these si/shRNAs kill cancer cells through canonical RNAi by targeting the 3’UTR of critical survival genes in a unique form of off-target effect. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
4 Samples
Download data: XLSX
Series
Accession:
GSE102780
ID:
200102780

PubMed Full text in PMC Similar studies SRA Run Selector

11.

CD95L mRNA is toxic to cells [SmallRNA_CD95L.50hrs.Drosha_ko]

(Submitter supplied) >80% of a large number of tested siRNAs and shRNAs targeting CD95 or CD95 ligand (CD95L) induce a form of cell death that is characterized by the simultaneous activation of multiple death pathways and preferentially affects transformed and cancer stem cells. We now show that these si/shRNAs kill cancer cells through canonical RNAi by targeting the 3’UTR of critical survival genes in a unique form of off-target effect. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
4 Samples
Download data: XLSX
Series
Accession:
GSE102779
ID:
200102779

PubMed Full text in PMC Similar studies SRA Run Selector

12.

CD95L mRNA is toxic to cells [SmallRNA_AGOpulldownCD95L_50hrs_HeyA8_CD95KO]

(Submitter supplied) >80% of a large number of tested siRNAs and shRNAs targeting CD95 or CD95 ligand (CD95L) induce a form of cell death that is characterized by the simultaneous activation of multiple death pathways and preferentially affects transformed and cancer stem cells. We now show that these si/shRNAs kill cancer cells through canonical RNAi by targeting the 3’UTR of critical survival genes in a unique form of off-target effect. more...
Organism:
Homo sapiens
Type:
Other
Platform:
GPL20301
4 Samples
Download data: XLS
Series
Accession:
GSE102777
ID:
200102777

PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector

13.

CD95/Fas ligand mRNA is toxic to cells through more than one mechanism

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
36 Samples
Download data
Series
Accession:
GSE219226
ID:
200219226

PubMed Full text in PMC Similar studies

14.

CD95/Fas ligand mRNA is toxic to cells through more than one mechanism [DISE-64]

(Submitter supplied) Analysis of RISC bound short (s)RNAs in a HCT116 Drosha CD95 d.k.o. cell line expressing pLenti-CD95L and various CD95L mutant constructs.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
8 Samples
Download data: TXT
Series
Accession:
GSE219225
ID:
200219225

PubMed Full text in PMC Similar studies

15.

CD95/Fas ligand mRNA is toxic to cells through more than one mechanism [DISE-63]

(Submitter supplied) Analysis of RISC bound short (s)RNAs in a HCT116 wild-type, Drosha k.o., and Ago 1/2/3 k.o. cells expressing pLenti-CD95L NP or pLenti empty vector.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
12 Samples
Download data: TXT
Series
Accession:
GSE219224
ID:
200219224

PubMed Full text in PMC Similar studies

16.

CD95/Fas ligand mRNA is toxic to cells through more than one mechanism [DISE-47]

(Submitter supplied) Analysis of RISC bound short (s)RNAs in a HCT116 Drosha CD95 d.k.o. cell line expressing pLenti-CD95L and various CD95L mutant constructs.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
10 Samples
Download data: TXT
Series
Accession:
GSE219223
ID:
200219223

PubMed Full text in PMC Similar studies

17.

CD95/Fas ligand mRNA is toxic to cells through more than one mechanism [DISE-46]

(Submitter supplied) Analysis of RISC bound short (s)RNAs in a HCT116 wild-type, Drosha k.o., and Dicer k.o. cells expressing pLenti-CD95L NP or pLenti empty vector.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL20301
6 Samples
Download data: TXT
Series
Accession:
GSE219222
ID:
200219222

PubMed Full text in PMC Similar studies

18.

CD95/Fas increases stemness in cancer cells by inducing a STAT1 dependent Type I interferon response

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by array; Genome binding/occupancy profiling by high throughput sequencing
Platforms:
GPL15456 GPL10558
6 Samples
Download data: BEDGRAPH, TXT
Series
Accession:
GSE81860
ID:
200081860

PubMed Full text in PMC Similar studies Analyze with GEO2R

19.

CD95/Fas increases stemness in cancer cells by inducing a STAT1 dependent Type I interferon response [ChIP-seq]

(Submitter supplied) CD95 was found to be important for both the formation of CSCs and their maintenance. Using a stable isotope labeling by amino acids in cell culture (SILAC) analysis we have now identified STAT1 as a critical gene that mediates the CSC-driving activity of CD95. We report that chronic stimulation of CD95 by either agonist antibodies, soluble CD95L or stably expressed membrane CD95L causes both serine and tyrosine phosphorylation of STAT1 and activation of STAT1 regulated genes. more...
Organism:
Homo sapiens
Type:
Genome binding/occupancy profiling by high throughput sequencing
Platform:
GPL15456
2 Samples
Download data: BEDGRAPH, TXT
Series
Accession:
GSE81859
ID:
200081859

PubMed Full text in PMC Similar studies SRA Run Selector

20.

CD95/Fas increases stemness in cancer cells by inducing a STAT1 dependent Type I interferon response [array]

(Submitter supplied) CD95 was found to be important for both the formation of CSCs and their maintenance. Using a stable isotope labeling by amino acids in cell culture (SILAC) analysis we have now identified STAT1 as a critical gene that mediates the CSC-driving activity of CD95. We report that chronic stimulation of CD95 by either agonist antibodies, soluble CD95L or stably expressed membrane CD95L causes both serine and tyrosine phosphorylation of STAT1 and activation of STAT1 regulated genes. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL10558
4 Samples
Download data: TXT
Series
Accession:
GSE81853
ID:
200081853

PubMed Full text in PMC Similar studies Analyze with GEO2R

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filters: Manage Filters

db=gds|term=|query=1|qty=2|blobid=MCID_67490c3c462e1a751e182658|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Important Links

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Genes & Expression > Gene Expression Omnibus (GEO) Datasets
Support Center